Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy [1, 2]. As there is a spectr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Mara W., Watanabe-Smith, Kevin, Tyner, Jeffrey W., Tognon, Cristina E., Druker, Brian J., Borate, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381100/
https://www.ncbi.nlm.nih.gov/pubmed/32754299
http://dx.doi.org/10.18632/oncotarget.27656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381100/
https://www.ncbi.nlm.nih.gov/pubmed/32754299
http://dx.doi.org/10.18632/oncotarget.27656

Ejemplares similares